# Transcend Therapeutics

**Type:** Biotech company  
**Focus:** MDMA-like compounds for PTSD  
**Lead Asset:** TSND-201 (methylone)  
**Status:** Breakthrough Therapy Designation; National Priority Voucher recipient

## Overview

Transcend Therapeutics is developing methylone (TSND-201), an MDMA-like compound for PTSD treatment. The company received FDA Breakthrough Therapy Designation and was awarded a National Priority Voucher on April 24, 2026 under the Trump Executive Order on psychedelics.

## Strategic Context

Methylone represents a distinct chemical entity from MDMA, potentially addressing the regulatory challenges that led to MDMA-AT's FDA rejection. By pursuing a related molecule with cleaner trial design, Transcend is attempting to capture MDMA's therapeutic mechanism while avoiding its regulatory history.

## Timeline

- **2026-04-24** — Received FDA National Priority Voucher for TSND-201 methylone (PTSD) under Trump Executive Order, compressing review timeline to 1-2 months post-application